PDE4A and seborrheic dermatitis: Roflumilast cream (0.3%) is a novel, nonsteroidal cream, that has demonstrated safety and efficacy for use in plaque psoriasis, seborrheic dermatitis, and mild-to-moderate atopic dermatitis by inhibiting phoshodiesterase 4 (PDE4).6,7 PDE4 inhibitors have been shown to reduce hyperproliferation of keratinocytes in human skin,8 and, therefore, could potentially aid in the treatment of follicular keratotic disorders.